Clinical Trials Directory

Trials / Completed

CompletedNCT01142596

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Phase 3 ; Protocol No. P06125)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
201 (actual)
Sponsor
Organon and Co · Industry
Sex
All
Age
20 Years – 64 Years
Healthy volunteers
Not accepted

Summary

This is a multi-site, randomized fixed-flexible dose long-term study of asenapine in participants with schizophrenia. The first six weeks of the study will be double-blind and the remainder of the study will be open label. Participants in this study consist of participants who have completed the preceding short-term study (P06124 \[NCT01098110\]), who meet the inclusion criteria and wish to continue receiving study drug, and whom the investigators have deemed eligible for study participation. Participants who were on placebo twice daily (BID) in core trial P06124 will get placebo for the first 2 weeks then 5 mg asenapine BID for the next 4 weeks of double blind treatment, and will be re-randomized after week 6 to asenapine 5 mg BID or asenapine 10 mg BID. Participants who were on asenapine 5 mg BID in core trial P06124 will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID. Participants who were on asenapine 10 mg BID in core trial P06124 will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID. After re-randomization, drug will be administered open-label for 46 weeks. During this period dose is flexible can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability.

Conditions

Interventions

TypeNameDescription
DRUGAsenapineAsenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
DRUGPlaceboPlacebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)

Timeline

Start date
2010-05-25
Primary completion
2015-04-22
Completion
2015-04-22
First posted
2010-06-11
Last updated
2024-05-28
Results posted
2016-05-18

Source: ClinicalTrials.gov record NCT01142596. Inclusion in this directory is not an endorsement.